What were the main drivers of revenue for Eli Lilly in the third quarter of 2009?

The filing details revenue generated from various product categories. Investors should examine the performance of key drugs, such as those in areas like diabetes, oncology, or neuroscience, to understand the primary revenue sources and growth trends during the quarter.

How much is Eli Lilly investing in Research and Development (R&D)?

The 'Management's Discussion and Analysis' section of the 10-Q will provide specific figures for R&D expenditures. This is crucial for investors to assess the company's commitment to innovation and its future product pipeline.

Are there any significant legal or regulatory issues that investors should be aware of?

Item 1 of Part II, 'Legal Proceedings,' and other relevant sections will outline any ongoing or recently resolved legal matters, government investigations, or regulatory challenges that could potentially impact the company's financial results or operations.

What is Eli Lilly's current financial position in terms of cash and debt?

The balance sheet provides a clear view of Eli Lilly's assets and liabilities. Investors can review the reported cash and cash equivalents, as well as the company's debt obligations, to gauge its financial stability and liquidity.

LLY 10-Q Quarterly Report Q3 FY2009 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company (LLY) reported its financial results for the period ending September 29, 2009, in its 10-Q filing. The company's performance reflects the ongoing challenges and opportunities within the pharmaceutical industry during this period. Investors should pay close attention to revenue drivers, product pipeline developments, and any significant legal or regulatory matters that could impact future profitability and growth. The filing provides a snapshot of the company's financial health and operational performance during the third quarter of 2009, offering insights into its ability to navigate market dynamics and maintain its competitive position.

Financial Highlights

45 data points

Beta

Revenue

$5.56B

0.8% Gross Margin

Net Income

$941.80M

0.2% Net Margin

Total Assets

$27.13B

Cash & Equivalents

$3.85B

Free Cash Flow

$1.31B

Financial Statements

Beta

Revenue	$5.56B
Cost of Revenue	$1.05B
Gross Profit	$4.51B
R&D Expenses	$1.12B
SG&A Expenses	$1.70B
Interest Expense	$59.20M
Net Income	$941.80M

Key Highlights

1Revenue performance during the quarter, driven by key product sales and any emerging trends.
2Details on operating expenses, including research and development (R&D) investments and selling, general, and administrative (SG&A) costs.
3Net income and earnings per share (EPS) for the period, indicating overall profitability.
4Balance sheet highlights, such as cash position, debt levels, and working capital management.
5Cash flow from operations, investing, and financing activities, providing insight into cash generation and utilization.
6Any disclosures regarding significant legal proceedings or regulatory events that could have a material impact on the company.
7Management's outlook and discussion on future financial condition and results of operations, including forward-looking statements.

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 2009

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions